The Experimental Therapeutics in Cancer Program at Children's Mercy Hospitals and Clinics leads the area with expertise in pediatric clinical trials. The program contributes key research leading to the discovery of new cancer-fighting drugs, along with giving pediatric cancer patients more innovative treatment options.
Experimental Therapeutics Staff
Our staff is led by a physician who is board-certified in hematology/oncology and pharmacology. Led by Kathleen Neville, MD, staff members include nurse practitioners and research nurses experienced in treating pediatric cancer patients. Our doctors and research scientists continue to apply knowledge from research studies directly to improving pediatric cancer care.
- The program is currently involved with more than 15 studies of phase I and phase II cancer drugs.
- Our extensive track record in pharmacology clinical trials research includes leadership in pediatric labeling for 35 separate medications since the Best Pharmaceuticals for Children Act of 2002.
- The program has been selected to serve as the clinical pharmacology core for the Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) and the Neuroblastoma Medulloblastoma Translational Research Consortium.